首页 > 最新文献

Annals of Clinical Gastroenterology and Hepatology最新文献

英文 中文
Hyperparathyroidism in celiac disease: A case study from UAE 乳糜泻的甲状旁腺功能亢进:来自阿联酋的一例研究
Pub Date : 2020-04-07 DOI: 10.29328/JOURNAL.ACGH.1001016
M. Fayadh, S. Awadh, Loai El Kiwisney, Abdulhaseeb Quadri, P. Shetty, Mervat Naguib
Celiac disease affects 1% of the world population; however it is under diagnosed in UAE. The disease has many clinical manifestations, ranging from severe malabsorption to minimally symptomatic or non-symptomatic presentation. Hypocalcaemia is a common finding in celiac disease and could be the only presentation of the disease; however hypercalcemia has been previously reported in patients with celiac disease either due to primary hyperparathyroidism or tertiary hyperparathyroidism due to prolonged hypocalcaemia. A normal calcium level on the other hand in patients with untreated celiac disease who also have primary hyperparathyroidism can be due to interplay of these two conditions and may delay the diagnosis of primary Hyperparathyroidism. We report the very first case from our practice in UAE with untreated celiac disease and normal calcium level at presentation, where a diagnosis of primary hyperparathyroidism was not entertained initially. Patient went on gluten free diet which then caused normalization of intestinal abnormalities and likely calcium absorption manifesting as hypercalcemia on subsequent labs. This led to further work up and finally the diagnosis of Primary hyperparathyroidism due to parathyroid adenoma.
乳糜泻影响了世界1%的人口;然而,在阿联酋诊断不足。该病有多种临床表现,从严重的吸收不良到轻微症状或无症状。低钙血症是乳糜泻的常见症状也可能是乳糜泻的唯一表现;然而,高钙血症先前在乳糜泻患者中有报道,要么是由于原发性甲状旁腺功能亢进,要么是由于长期低钙导致的三发甲状旁腺功能亢进。另一方面,患有原发性甲状旁腺功能亢进的未治疗乳糜泻患者的正常钙水平可能是由于这两种情况的相互作用,可能延迟原发性甲状旁腺功能亢进的诊断。我们报告了我们在阿联酋的第一例乳糜泻未经治疗的病例,就诊时钙水平正常,最初没有考虑原发性甲状旁腺功能亢进的诊断。病人开始无麸质饮食这导致了肠道异常的正常化和钙吸收在随后的实验中表现为高钙血症。这导致进一步的工作,并最终诊断原发性甲状旁腺功能亢进由于甲状旁腺瘤。
{"title":"Hyperparathyroidism in celiac disease: A case study from UAE","authors":"M. Fayadh, S. Awadh, Loai El Kiwisney, Abdulhaseeb Quadri, P. Shetty, Mervat Naguib","doi":"10.29328/JOURNAL.ACGH.1001016","DOIUrl":"https://doi.org/10.29328/JOURNAL.ACGH.1001016","url":null,"abstract":"Celiac disease affects 1% of the world population; however it is under diagnosed in UAE. The disease has many clinical manifestations, ranging from severe malabsorption to minimally symptomatic or non-symptomatic presentation. Hypocalcaemia is a common finding in celiac disease and could be the only presentation of the disease; however hypercalcemia has been previously reported in patients with celiac disease either due to primary hyperparathyroidism or tertiary hyperparathyroidism due to prolonged hypocalcaemia. A normal calcium level on the other hand in patients with untreated celiac disease who also have primary hyperparathyroidism can be due to interplay of these two conditions and may delay the diagnosis of primary Hyperparathyroidism. We report the very first case from our practice in UAE with untreated celiac disease and normal calcium level at presentation, where a diagnosis of primary hyperparathyroidism was not entertained initially. Patient went on gluten free diet which then caused normalization of intestinal abnormalities and likely calcium absorption manifesting as hypercalcemia on subsequent labs. This led to further work up and finally the diagnosis of Primary hyperparathyroidism due to parathyroid adenoma.","PeriodicalId":252959,"journal":{"name":"Annals of Clinical Gastroenterology and Hepatology","volume":"64 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117336984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Laparoscopic anterior transgastric cystogastrostomy for the treatment of pancreatic pseudocysts 腹腔镜前路经胃囊胃造口术治疗胰腺假性囊肿
Pub Date : 2020-04-06 DOI: 10.29328/JOURNAL.ACGH.1001015
F. Yetisir, K. Güzel
Introduction: Pancreatic pseudocysts (PPs) are mostly delayed complications of acute or chronic pancreatitis and trauma. Pancreatic pseudocysts are usually managed by supportive medical treatment without surgical procedure. All the surgical interventions (percutaneous, endoscopic or surgical approaches) are based on the location, size, symptoms, complications of the pancreatic pseudocyst and medical condition of the patients. Recently, laparoscopic cystogastrostomy has become most appropriate approach especially for retrogastric pancreatic pseudocysts. In this study, we would like to report results of laparoscopic anterior transgastric cystogastrostomy by using linear articulated endo GIA stapler (Covidien medium thick purple) and versa-lifter (versa lifter®, laparoscopic retractor, manufactured by protomedlabs, France) in 14 pancreatic pseudocysts patients. Methods: We retrospectively analyzed data of patients with pancreatic pseudocysts treated by laparoscopic anterior transgastric cystogastrostomy from September 2010 to October 2014. All of the patients were controlled for the recurrence of pancreatic pseudocysts in February 2017. Results: 14 patients with pancreatic pseudocysts were managed by laparoscopic anterior transgastric cysto-gastrostomy. Conversion was performed in only one patient (7%). There were no symptoms and signs of recurrence of pancreatic pseudocyst during on average 43.6 months follow up time. Conclusion: Laparoscopic cystogastrostomy by using articulated linear endo-GIA stapler and versa-lifter is a safe and effective method for management of appropriate retro-gastric pancreatic pseudocysts.
胰腺假性囊肿(PPs)多为急性或慢性胰腺炎和创伤的迟发性并发症。胰腺假性囊肿通常通过支持性药物治疗而不需要手术治疗。所有的手术干预(经皮、内窥镜或外科手术)都是基于胰腺假性囊肿的位置、大小、症状、并发症和患者的医疗状况。近年来,腹腔镜胆囊胃吻合术已成为治疗胃后胰腺假性囊肿最合适的方法。在这项研究中,我们想报告使用线性关节式内腔GIA吻合器(Covidien中厚紫色)和versa-lifter (versa lifter®,腹腔镜牵开器,protomedlabs,法国制造)对14例胰腺假性囊肿患者进行腹腔镜前路经胃囊胃造口术的结果。方法:回顾性分析2010年9月至2014年10月腹腔镜前路经胃囊胃造口术治疗胰腺假性囊肿患者的资料。所有患者均于2017年2月进行胰腺假性囊肿复发控制。结果:14例胰腺假性囊肿采用腹腔镜前路经胃囊胃造口术治疗。只有1例患者(7%)进行了转换。平均随访43.6个月,无胰腺假性囊肿复发的症状和体征。结论:应用关节式内镜下吻合器和反举器行腹腔镜胆囊胃吻合术是一种安全有效的治疗胃后胰假性囊肿的方法。
{"title":"Laparoscopic anterior transgastric cystogastrostomy for the treatment of pancreatic pseudocysts","authors":"F. Yetisir, K. Güzel","doi":"10.29328/JOURNAL.ACGH.1001015","DOIUrl":"https://doi.org/10.29328/JOURNAL.ACGH.1001015","url":null,"abstract":"Introduction: Pancreatic pseudocysts (PPs) are mostly delayed complications of acute or chronic pancreatitis and trauma. Pancreatic pseudocysts are usually managed by supportive medical treatment without surgical procedure. All the surgical interventions (percutaneous, endoscopic or surgical approaches) are based on the location, size, symptoms, complications of the pancreatic pseudocyst and medical condition of the patients. Recently, laparoscopic cystogastrostomy has become most appropriate approach especially for retrogastric pancreatic pseudocysts. In this study, we would like to report results of laparoscopic anterior transgastric cystogastrostomy by using linear articulated endo GIA stapler (Covidien medium thick purple) and versa-lifter (versa lifter®, laparoscopic retractor, manufactured by protomedlabs, France) in 14 pancreatic pseudocysts patients. Methods: We retrospectively analyzed data of patients with pancreatic pseudocysts treated by laparoscopic anterior transgastric cystogastrostomy from September 2010 to October 2014. All of the patients were controlled for the recurrence of pancreatic pseudocysts in February 2017. Results: 14 patients with pancreatic pseudocysts were managed by laparoscopic anterior transgastric cysto-gastrostomy. Conversion was performed in only one patient (7%). There were no symptoms and signs of recurrence of pancreatic pseudocyst during on average 43.6 months follow up time. Conclusion: Laparoscopic cystogastrostomy by using articulated linear endo-GIA stapler and versa-lifter is a safe and effective method for management of appropriate retro-gastric pancreatic pseudocysts.","PeriodicalId":252959,"journal":{"name":"Annals of Clinical Gastroenterology and Hepatology","volume":"130 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127600148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Evaluation of outcomes of 8-week therapy with ledipasvir/sofosbuvir or glecaprevir/pibrentasvir in veterans with hepatitis C infection 评估丙型肝炎感染退伍军人接受雷地帕韦/索非布韦或格列韦/匹布他韦8周治疗的结果
Pub Date : 2019-11-13 DOI: 10.29328/journal.acgh.1001011
L. Lemoine, M. Segarra‐Newnham
{"title":"Evaluation of outcomes of 8-week therapy with ledipasvir/sofosbuvir or glecaprevir/pibrentasvir in veterans with hepatitis C infection","authors":"L. Lemoine, M. Segarra‐Newnham","doi":"10.29328/journal.acgh.1001011","DOIUrl":"https://doi.org/10.29328/journal.acgh.1001011","url":null,"abstract":"","PeriodicalId":252959,"journal":{"name":"Annals of Clinical Gastroenterology and Hepatology","volume":"23 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128098185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Addition of Simvastatin to Carvedilol and Endoscopic Variceal Ligation improves rebleeding and survival in patients with Child-Pugh A and B class but not in Child Pugh C class 在卡维地洛和内镜下静脉曲张结扎中加入辛伐他汀可以改善Child-Pugh A和B级患者的再出血和生存,但对Child-Pugh C级患者没有改善
Pub Date : 2019-08-20 DOI: 10.29328/journal.acgh.1001010
S. Jha, Kuldeep Saharawat, R. Keshari, Praveen Jha, S. Purkayastha, R. Ranjan
Background: Even with current standard treatment after variceal bleeding which includes combination of nonselective b-blockers and repeated endoscopic variceal ligation, the risk of rebleeding and mortality are high. Statins exhibit an antifi brotic effect and improves HVPG. We evaluated whether addition of simvastatin to carvedilol plus EVL therapy reduces variceal rebleeds or death in patients with cirrhosis.
背景:即使采用目前的标准治疗,包括联合非选择性b受体阻滞剂和反复内镜下静脉曲张结扎,再出血和死亡率的风险也很高。他汀类药物表现出抗炎作用并改善HVPG。我们评估了辛伐他汀加卡维地洛和EVL治疗是否能减少肝硬化患者的静脉曲张再出血或死亡。
{"title":"Addition of Simvastatin to Carvedilol and Endoscopic Variceal Ligation improves rebleeding and survival in patients with Child-Pugh A and B class but not in Child Pugh C class","authors":"S. Jha, Kuldeep Saharawat, R. Keshari, Praveen Jha, S. Purkayastha, R. Ranjan","doi":"10.29328/journal.acgh.1001010","DOIUrl":"https://doi.org/10.29328/journal.acgh.1001010","url":null,"abstract":"Background: Even with current standard treatment after variceal bleeding which includes combination of nonselective b-blockers and repeated endoscopic variceal ligation, the risk of rebleeding and mortality are high. Statins exhibit an antifi brotic effect and improves HVPG. We evaluated whether addition of simvastatin to carvedilol plus EVL therapy reduces variceal rebleeds or death in patients with cirrhosis.","PeriodicalId":252959,"journal":{"name":"Annals of Clinical Gastroenterology and Hepatology","volume":"12 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131386208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Endoscopic treatment of pancreatic diseases via Duodenal Minor Papilla: 135 cases treated by Sphyncterotomy, Endoscopic Pancreatic Duct Balloon Dilation (EPDBD), and Pancreatic Stenting (EPS) 经十二指肠小乳头内镜治疗胰腺疾病:经括约肌切开术、内镜胰管球囊扩张术(EPDBD)、胰支架置入术(EPS) 135例
Pub Date : 2019-07-08 DOI: 10.29328/JOURNAL.ACGH.1001009
Tadao Tsuji, G. Sun, A. Sugiyama, Y. Amano, S. Mano, T Shinobi, Hiroshi Tanaka, M. Kubochi, Kazuo Ohishi, Y. Moriya, M. Ono, T. Masuda, H. Shinozaki, H. Kaneda, Hideyuki Katsura, T. Mizutani, K. Miura, M. Katoh, K. Yamafuji, K. Takeshima, N. Okamoto, Y. Hoshino, N. Tsurumi, S. Hisada, J. Won, T. Kogiso, K Yatsuji, M. Iimura, Toshiharu Kakimoto, S Nyuhzuki
Treatments via the minor papilla is effective where the deep cannulation via the major papilla is impossible in such cases as [1] the Wirsung’s duct is infl ammatory narrowed, bent or obstructed by impacted stones [2] pancreatic duct divisum (complete or incomplete) [3], maljunction of pancreatico-biliary union with stones [4], pancreatic stones in the Santorini’s duct. In [1,2] cases, the pancreatic juice fl ow via the major papilla decreases, while that of the minor papilla increases. Then the size of minor papilla and its orifi ce shows corresponding enlargement. This substitutional mechanism is an advantage when undertaking our new method. Since the pancreatic juice fl ow is maintained via the minor papilla in these cases, accurate and careful endoscopic skills are necessary to prevent pancreatitis due to the occlusion of the Santorini’s duct after this procedure. We have experienced 135 cases treated via minor papilla in these 27 years, so we would like to report about its safety and effi cacy. More Information Submitted: 20 June 2019 Approved: 05 July 2019 Published: 08 July 2019 How to cite this article: Tsuji T, Sun G, Sugiyama A, Amano Y, Mano S, et al. Endoscopic treatment of pancreatic diseases via Duodenal Minor Papilla: 135 cases treated by Sphincterotomy, Endoscopic Pancreatic Duct Balloon Dilation (EPDBD), and Pancreatic Stenting (EPS). Ann Clin Gastroenterol Hepatol. 2019; 3: 012-019. https://doi.org.10.29328/journal.acgh.1001009 Copyright: © 2019 Tsuji T, et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
在不能通过大乳头进行深层插管的情况下,通过小乳头进行治疗是有效的,如[1]Wirsung导管炎症性狭窄、弯曲或因结石阻塞[2]胰管分裂(完全或不完全)[3],胰胆联合与结石的不结合[4],圣托里尼管中的胰结石。在[1,2]病例中,经大乳头的胰液流量减少,而经小乳头的胰液流量增加。小乳头及其孔口相应增大。当采用我们的新方法时,这种替代机制是一个优势。由于在这些病例中,胰液的流动是通过小乳头维持的,因此准确和仔细的内窥镜技术是必要的,以防止手术后由于圣托里尼管阻塞而导致胰腺炎。在这27年中,我们经历了135例通过小乳头治疗的病例,所以我们想报告它的安全性和有效性。更多信息提交日期:2019年6月20日批准日期:2019年7月05日发布日期:2019年7月08日本文引用方式:Tsuji T, Sun G, Sugiyama A, Amano Y, Mano S,等。经十二指肠小乳头内镜治疗胰腺疾病:经括约肌切开术、内镜胰管球囊扩张术(EPDBD)、胰支架置入术(EPS)治疗135例Ann clinical Gastroenterol Hepatol; 2019;3: 012 - 019。https://doi.org.10.29328/journal.acgh.1001009版权所有:©2019 Tsuji T, et al。这是一篇在知识共享署名许可下发布的开放获取文章,该许可允许在任何媒体上不受限制地使用、分发和复制,只要原始作品被适当引用
{"title":"Endoscopic treatment of pancreatic diseases via Duodenal Minor Papilla: 135 cases treated by Sphyncterotomy, Endoscopic Pancreatic Duct Balloon Dilation (EPDBD), and Pancreatic Stenting (EPS)","authors":"Tadao Tsuji, G. Sun, A. Sugiyama, Y. Amano, S. Mano, T Shinobi, Hiroshi Tanaka, M. Kubochi, Kazuo Ohishi, Y. Moriya, M. Ono, T. Masuda, H. Shinozaki, H. Kaneda, Hideyuki Katsura, T. Mizutani, K. Miura, M. Katoh, K. Yamafuji, K. Takeshima, N. Okamoto, Y. Hoshino, N. Tsurumi, S. Hisada, J. Won, T. Kogiso, K Yatsuji, M. Iimura, Toshiharu Kakimoto, S Nyuhzuki","doi":"10.29328/JOURNAL.ACGH.1001009","DOIUrl":"https://doi.org/10.29328/JOURNAL.ACGH.1001009","url":null,"abstract":"Treatments via the minor papilla is effective where the deep cannulation via the major papilla is impossible in such cases as [1] the Wirsung’s duct is infl ammatory narrowed, bent or obstructed by impacted stones [2] pancreatic duct divisum (complete or incomplete) [3], maljunction of pancreatico-biliary union with stones [4], pancreatic stones in the Santorini’s duct. In [1,2] cases, the pancreatic juice fl ow via the major papilla decreases, while that of the minor papilla increases. Then the size of minor papilla and its orifi ce shows corresponding enlargement. This substitutional mechanism is an advantage when undertaking our new method. Since the pancreatic juice fl ow is maintained via the minor papilla in these cases, accurate and careful endoscopic skills are necessary to prevent pancreatitis due to the occlusion of the Santorini’s duct after this procedure. We have experienced 135 cases treated via minor papilla in these 27 years, so we would like to report about its safety and effi cacy. More Information Submitted: 20 June 2019 Approved: 05 July 2019 Published: 08 July 2019 How to cite this article: Tsuji T, Sun G, Sugiyama A, Amano Y, Mano S, et al. Endoscopic treatment of pancreatic diseases via Duodenal Minor Papilla: 135 cases treated by Sphincterotomy, Endoscopic Pancreatic Duct Balloon Dilation (EPDBD), and Pancreatic Stenting (EPS). Ann Clin Gastroenterol Hepatol. 2019; 3: 012-019. https://doi.org.10.29328/journal.acgh.1001009 Copyright: © 2019 Tsuji T, et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited","PeriodicalId":252959,"journal":{"name":"Annals of Clinical Gastroenterology and Hepatology","volume":"2 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128918952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Transcatheter Arterial Embolization for the treatment of upper gastrointestinal bleeding 经导管动脉栓塞治疗上消化道出血
Pub Date : 2019-06-07 DOI: 10.29328/JOURNAL.ACGH.1001008
M. Habib, Majed Alshounat
Background: Transcatheter arterial embolization can be used for patients with recurrent bleeding from the upper gastrointestinal tract after failed endoscopic treatment. Our aim to identify the clinical and technical factors that infl uenced the outcome of transcatheter embolization for therapy of upper gastrointestinal bleeding after failed surgery or after failed endoscopic treatment in high risk surgical patients. Methods: We performed a prospective study to analysis of the 15 patients who underwent Transcatheter arterial embolization for nonvariceal upper gastrointestinal bleeding at Alshifa hospital from January 2015 to March 2019. The following variables were recorded: demographic data, time from bleeding start to TAE, units of packed red cells before TAE and units of packed plasma before Transcatheter arterial embolization and we analysis 30 days rebleeding rates and mortality. Results: Patients treated with Transcatheter arterial embolization (median age: 62 years, range: 14–79 years).The technical success rate of the embolization procedure was 100%. Time from bleeding start to TAE was 2.1 (1-4) days , units of packed red cells before Transcatheter arterial embolization was 12.8 (4-22) packed and units of packed plasma was 3.2 (2-5) packed. Following 30 days after embolization, 2 (13%) patients had repeated bleeding and 3 (20.0%) patients died. Conclusion: In our experience, arterial embolization is a safe and effective treatment method for upper gastrointestinal bleeding and a possible alternative to surgery for high-risk patients. Research Article Transcatheter Arterial Embolization for the treatment of upper gastrointestinal bleeding Mohammed Habib1* and Majed Alshounat2 1Consultant, Interventional Cardiologist, Head of Cardiology Department, Alshifa Hospital, Gaza, Palestine 2Consultant, interventional Cardiologist. Alshifa Hospital, Gaza, Palestine *Address for Correspondence: Mohammed Habib, MD, PhD, Alshifa Hospital, Cardiology Department, Gaza, Palestine, Tel: 00972599514060; Email: cardiomohammad@yahoo.com Submitted: 22 May 2019 Approved: 06 June 2019 Published: 07 June 2019 Copyright: © 2019 Habib M, et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited How to cite this article: Habib M, Alshounat M. Transcatheter Arterial Embolization for the treatment of upper gastrointestinal bleeding. Ann Clin Gastroenterol Hepatol. 2019; 3: 006-011. https://dx.doi.org/10.29328/journal.acgh.1001008 Introduction Acute nonvariceal upper gastrointestinal (GI) bleeding remains a challenging presentation due to signi icant morbidity and mortality rates, and about half of all cases of upper GI bleeding are caused by gastric and duodenal ulcers. Although irstline endoscopy achieves bleeding control in most patients, if this does not work, the mortality rate can be 5% to 10% because of
背景:经导管动脉栓塞可用于内镜治疗失败后复发的上消化道出血患者。我们的目的是确定影响经导管栓塞治疗手术失败或内镜治疗失败后高危手术患者上消化道出血结果的临床和技术因素。方法:我们对2015年1月至2019年3月在Alshifa医院接受经导管动脉栓塞治疗非静脉曲张上消化道出血的15例患者进行了前瞻性研究。记录以下变量:人口统计学数据,从出血开始到TAE的时间,TAE前的红细胞堆积单位和经导管动脉栓塞前的血浆堆积单位,并分析30天再出血率和死亡率。结果:经导管动脉栓塞治疗的患者(中位年龄:62岁,范围:14-79岁)。栓塞术的技术成功率为100%。从出血开始到TAE的时间为2.1(1-4)天,经导管动脉栓塞前红细胞填充单位为12.8(4-22)个,血浆填充单位为3.2(2-5)个。栓塞后30 d, 2例(13%)患者再次出血,3例(20.0%)患者死亡。结论:根据我们的经验,动脉栓塞是一种安全有效的治疗上消化道出血的方法,是治疗高危患者的一种可能的替代方法。研究文章经导管动脉栓塞治疗上消化道出血Mohammed Habib1* and Majed Alshounat2顾问医师,介入心脏病专家,巴勒斯坦加沙Alshifa医院心脏病科主任顾问医师,介入心脏病专家*通讯地址:穆罕默德·哈比卜,医学博士,巴勒斯坦加沙,阿希法医院心脏病科,电话:00972599514060;邮箱:cardiomohammad@yahoo.com提交时间:2019年5月22日批准时间:2019年6月06日发布时间:2019年6月07日版权所有:©2019 Habib M, et al.。这是一篇在知识共享署名许可下发布的开放获取文章,该许可允许在任何媒介上不受限制地使用、分发和复制,前提是正确引用原始作品。Ann clinical Gastroenterol Hepatol; 2019;3: 006 - 011。https://dx.doi.org/10.29328/journal.acgh.1001008简介急性非静脉曲张性上消化道(GI)出血仍然是一个具有挑战性的表现,由于显著的发病率和死亡率,大约一半的上消化道出血病例是由胃和十二指肠溃疡引起的。尽管一线内窥镜检查在大多数患者中实现了出血控制,但如果这不起作用,由于多种合并症、高龄和高输血需求,死亡率可达5%至10%。然而,老年人因消化性溃疡导致的严重上消化道出血的住院率和死亡率仍然很高[1-4]。手术也与高死亡率相关,因此,选择性经导管动脉栓塞(TAE)被认为是一种更安全的选择,因为可以避免剖腹手术,特别是在高危患者中。事实上,在许多机构中,TAE现在是对内镜治疗无效的上消化道大量动脉出血的一线干预措施。经导管动脉栓塞治疗上消化道出血由于胃和十二指肠有丰富的侧支供应,通常认为在Treitz韧带上方的上消化道动脉栓塞是非常安全的。我们报告了15例内镜手术失败后经动脉栓塞成功治疗上消化道出血的病例。方法2015年1月至2019年3月,我院收治15例上消化道出血患者。典型的候选患者表现为:1)大出血(24小时内至少输血3u)或血流动力学损害(收缩压< 90 mm Hg,心率> 100次/分钟或临床休克),2)内镜下难治性急性UGI出血,3)术后复发性出血。没有绝对的禁忌症,因为血管造影和栓塞可能需要作为挽救生命的程序。
{"title":"Transcatheter Arterial Embolization for the treatment of upper gastrointestinal bleeding","authors":"M. Habib, Majed Alshounat","doi":"10.29328/JOURNAL.ACGH.1001008","DOIUrl":"https://doi.org/10.29328/JOURNAL.ACGH.1001008","url":null,"abstract":"Background: Transcatheter arterial embolization can be used for patients with recurrent bleeding from the upper gastrointestinal tract after failed endoscopic treatment. Our aim to identify the clinical and technical factors that infl uenced the outcome of transcatheter embolization for therapy of upper gastrointestinal bleeding after failed surgery or after failed endoscopic treatment in high risk surgical patients. Methods: We performed a prospective study to analysis of the 15 patients who underwent Transcatheter arterial embolization for nonvariceal upper gastrointestinal bleeding at Alshifa hospital from January 2015 to March 2019. The following variables were recorded: demographic data, time from bleeding start to TAE, units of packed red cells before TAE and units of packed plasma before Transcatheter arterial embolization and we analysis 30 days rebleeding rates and mortality. Results: Patients treated with Transcatheter arterial embolization (median age: 62 years, range: 14–79 years).The technical success rate of the embolization procedure was 100%. Time from bleeding start to TAE was 2.1 (1-4) days , units of packed red cells before Transcatheter arterial embolization was 12.8 (4-22) packed and units of packed plasma was 3.2 (2-5) packed. Following 30 days after embolization, 2 (13%) patients had repeated bleeding and 3 (20.0%) patients died. Conclusion: In our experience, arterial embolization is a safe and effective treatment method for upper gastrointestinal bleeding and a possible alternative to surgery for high-risk patients. Research Article Transcatheter Arterial Embolization for the treatment of upper gastrointestinal bleeding Mohammed Habib1* and Majed Alshounat2 1Consultant, Interventional Cardiologist, Head of Cardiology Department, Alshifa Hospital, Gaza, Palestine 2Consultant, interventional Cardiologist. Alshifa Hospital, Gaza, Palestine *Address for Correspondence: Mohammed Habib, MD, PhD, Alshifa Hospital, Cardiology Department, Gaza, Palestine, Tel: 00972599514060; Email: cardiomohammad@yahoo.com Submitted: 22 May 2019 Approved: 06 June 2019 Published: 07 June 2019 Copyright: © 2019 Habib M, et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited How to cite this article: Habib M, Alshounat M. Transcatheter Arterial Embolization for the treatment of upper gastrointestinal bleeding. Ann Clin Gastroenterol Hepatol. 2019; 3: 006-011. https://dx.doi.org/10.29328/journal.acgh.1001008 Introduction Acute nonvariceal upper gastrointestinal (GI) bleeding remains a challenging presentation due to signi icant morbidity and mortality rates, and about half of all cases of upper GI bleeding are caused by gastric and duodenal ulcers. Although irstline endoscopy achieves bleeding control in most patients, if this does not work, the mortality rate can be 5% to 10% because of","PeriodicalId":252959,"journal":{"name":"Annals of Clinical Gastroenterology and Hepatology","volume":"38 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114143350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An uncommon cause of isolated ascites: Pseudomyxoma peritonei 孤立性腹水的罕见病因:腹膜假性粘液瘤
Pub Date : 2019-04-26 DOI: 10.29328/JOURNAL.ACGH.1001007
Louly Hady, I. Nassar, K. Znati, N. Kabbaj
Pseudomyxoma peritonei or Gelatinous Peritoneal Disease is a rare disease. We report a case treated in the department of Hepato-Gastroenterology at Ibn Sina Hospital in Rabat, of a 64-year-old male who presented with an abdominal pain and an increased volume of the abdomen corresponding to ascites. Imaging and anatomopathological study made it possible to diagnose the disease. However, given the general state of the patient, he is under palliative care. Case Report
腹膜假性黏液瘤或凝胶性腹膜病是一种罕见的疾病。我们报告一例在拉巴特Ibn Sina医院肝消化内科治疗的病例,患者为64岁男性,表现为腹痛和腹水所致的腹部体积增大。影像学及解剖病理学研究使本病的诊断成为可能。然而,鉴于病人的一般情况,他正在接受姑息治疗。病例报告
{"title":"An uncommon cause of isolated ascites: Pseudomyxoma peritonei","authors":"Louly Hady, I. Nassar, K. Znati, N. Kabbaj","doi":"10.29328/JOURNAL.ACGH.1001007","DOIUrl":"https://doi.org/10.29328/JOURNAL.ACGH.1001007","url":null,"abstract":"Pseudomyxoma peritonei or Gelatinous Peritoneal Disease is a rare disease. We report a case treated in the department of Hepato-Gastroenterology at Ibn Sina Hospital in Rabat, of a 64-year-old male who presented with an abdominal pain and an increased volume of the abdomen corresponding to ascites. Imaging and anatomopathological study made it possible to diagnose the disease. However, given the general state of the patient, he is under palliative care. Case Report","PeriodicalId":252959,"journal":{"name":"Annals of Clinical Gastroenterology and Hepatology","volume":"171 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"120981046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management outcome of intestinal obstruction done by integrated emergency surgical officers and its associated factors in selected district hospitals of South Wollo Zone, North East Ethiopia in 2019 G.C 2019年埃塞俄比亚东北部南沃罗区部分地区医院综合急诊外科医师治疗肠梗阻效果及相关因素分析
Pub Date : 1900-01-01 DOI: 10.29328/journal.acgh.1001029
Ademe Sewunet, Edmealem Afework, T. Belachew, Mengesha Zemen
Background: Intestinal obstruction (IO) is defined as a partial or complete blockage of the bowel that results in the failure of intestinal contents to pass through. It is a common cause of emergency surgical problems. IO has been the leading cause of acute abdomen in several African countries. Objective: To assess surgical management outcome of intestinal obstruction by IESO professionals and its associated factors of intestinal obstruction in surgically treated patients at South Wollo zone. Method: A cross-sectional study was done on 216 patients ‘the data was collected from medical cards of the patient by using a pretested data abstraction format. Three nurses were involved in the process of data collection. The collected data was cleaned, coded and analyzed by SPSS version 23 statistical package. First descriptive statics was done for categorical and analyzed using frequencies and percentage. Multivariable logistic regression models was used to determine the association factors on the management outcome of intestinal obstruction when p - value < 0.05 and the strength of statistical association was measured by adjusting odds ratio and 95% confidence interval. Statistical significance was taken at p - value < 0.05. Results: From all study participants about 177 (82%) of them had good surgical outcome. Study participants who were managed by 1-3 years of work experience of IESO {(p = 0.004, AOR (95% CI) = 7.2[1.89, 27.68]}, preoperatively diagnosed as small bowel obstruction {(p = 0.001, AOR (95% CI) = 4.5[1.91, 10.40], Surgery conducted at day time {(p = 0.03, AOR (95% CI) = 2.8[1.06, 7.16]} had shown positive association with management outcome of intestinal obstruction conducted by IESO professionals. Conclusion and recommendation: Majority patients with intestinal obstruction had good surgical outcome done by IESO professionals. Year of experience of IESO Workers, preoperative diagnosis and time of surgery of the respondents had shown positive association for the occurrence of chronic liver disease whereas. In this study we can conclude that surgeries of intestinal obstruction conducted by IESO professionals are as good as intestinal obstruction surgeries conducted by physicians so there is a need to train more IESO professionals to deliver decentralized surgical service for rural areas.
背景:肠梗阻(IO)被定义为肠道部分或完全堵塞,导致肠内容物无法通过。这是紧急外科问题的常见原因。在一些非洲国家,腹膜炎是导致急腹症的主要原因。目的:评价南沃罗地区IESO专业人员对手术患者肠梗阻的手术治疗效果及其相关因素。方法:对216例患者进行横断面研究,采用预测试的数据抽取格式,从患者的医疗卡中收集数据。三名护士参与了数据收集过程。收集的数据用SPSS 23版统计软件包进行清洗、编码和分析。首先对分类进行描述性统计,并使用频率和百分比进行分析。当p值< 0.05时,采用多变量logistic回归模型确定影响肠梗阻治疗结果的相关因素,并通过调整优势比和95%置信区间来衡量统计相关性的强弱。p值< 0.05,差异有统计学意义。结果:177例(82%)患者手术效果良好。具有1-3年IESO工作经验{(p = 0.004, AOR (95% CI) = 7.2[1.89, 27.68]}、术前诊断为小肠梗阻{(p = 0.001, AOR (95% CI) = 4.5[1.91, 10.40]、日间手术{(p = 0.03, AOR (95% CI) = 2.8[1.06, 7.16]}的研究参与者与IESO专业人员对肠梗阻的处理结果呈正相关。结论和建议:IESO专业人员对大多数肠梗阻患者的手术效果良好。调查对象的IESO工作年限、术前诊断和手术时间与慢性肝病的发生呈正相关。在本研究中,我们可以得出结论,IESO专业人员进行的肠梗阻手术与医生进行的肠梗阻手术一样好,因此需要培训更多的IESO专业人员,为农村地区提供分散的手术服务。
{"title":"Management outcome of intestinal obstruction done by integrated emergency surgical officers and its associated factors in selected district hospitals of South Wollo Zone, North East Ethiopia in 2019 G.C","authors":"Ademe Sewunet, Edmealem Afework, T. Belachew, Mengesha Zemen","doi":"10.29328/journal.acgh.1001029","DOIUrl":"https://doi.org/10.29328/journal.acgh.1001029","url":null,"abstract":"Background: Intestinal obstruction (IO) is defined as a partial or complete blockage of the bowel that results in the failure of intestinal contents to pass through. It is a common cause of emergency surgical problems. IO has been the leading cause of acute abdomen in several African countries. Objective: To assess surgical management outcome of intestinal obstruction by IESO professionals and its associated factors of intestinal obstruction in surgically treated patients at South Wollo zone. Method: A cross-sectional study was done on 216 patients ‘the data was collected from medical cards of the patient by using a pretested data abstraction format. Three nurses were involved in the process of data collection. The collected data was cleaned, coded and analyzed by SPSS version 23 statistical package. First descriptive statics was done for categorical and analyzed using frequencies and percentage. Multivariable logistic regression models was used to determine the association factors on the management outcome of intestinal obstruction when p - value < 0.05 and the strength of statistical association was measured by adjusting odds ratio and 95% confidence interval. Statistical significance was taken at p - value < 0.05. Results: From all study participants about 177 (82%) of them had good surgical outcome. Study participants who were managed by 1-3 years of work experience of IESO {(p = 0.004, AOR (95% CI) = 7.2[1.89, 27.68]}, preoperatively diagnosed as small bowel obstruction {(p = 0.001, AOR (95% CI) = 4.5[1.91, 10.40], Surgery conducted at day time {(p = 0.03, AOR (95% CI) = 2.8[1.06, 7.16]} had shown positive association with management outcome of intestinal obstruction conducted by IESO professionals. Conclusion and recommendation: Majority patients with intestinal obstruction had good surgical outcome done by IESO professionals. Year of experience of IESO Workers, preoperative diagnosis and time of surgery of the respondents had shown positive association for the occurrence of chronic liver disease whereas. In this study we can conclude that surgeries of intestinal obstruction conducted by IESO professionals are as good as intestinal obstruction surgeries conducted by physicians so there is a need to train more IESO professionals to deliver decentralized surgical service for rural areas.","PeriodicalId":252959,"journal":{"name":"Annals of Clinical Gastroenterology and Hepatology","volume":"58 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114942686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
AsdamarinTM relieves functional dyspepsia in healthy adults in only 7 days: A randomized, double-blind, placebo-controlled pilot study AsdamarinTM仅在7天内缓解健康成人的功能性消化不良:一项随机、双盲、安慰剂对照的试点研究
Pub Date : 1900-01-01 DOI: 10.29328/journal.acgh.1001028
Daguet David, Venkataramana Sudeep Heggar, Thomas Justin V, K. Shyam Prasad
Functional dyspepsia (FD) is a prevalent global health concern increasing with years. Inspired by the Traditional Chinese Medicine (TCM) liver-stomach disharmony syndrome in order to find a quick natural alternative treatment, a Ferula asafoetida-Silybum marianum (Asdamarin™) combined extract has been developed and proved its rapid efficiency and its safety with a 7-day randomized, double-blind, placebo-controlled pilot study (CTRI/2018/05/013993 dated 21/05/2018) conducted on 70 healthy human volunteers (aged 18–60 years) supplemented with 250 mg / twice a day of either a placebo or Asdamarin™. Subjects were evaluated from baseline to the end of the study (EOS) through changes in Gastrointestinal Symptom Rating Scale (GSRS), changes in Glasgow Dyspepsia Severity Score (GDSS) and changes in the short form of Nepean Dyspepsia Index (NDI-SF) for Quality of Life. Compared to the baseline a significant reduction (p < 0.001) of GDSS questionnaire score was noted in the Asdamarin™ group (from 5.66 ± 3.1 at baseline to 5.09 ± 2.8 at the End Of Study (EOS)) compared to placebo group (from 2.77 ± 1.3 baseline to 2.69 ± 1.3 EOS), a significant decrease (p < 0.001) of GSRS score noted in the Asdamarin™ group (from 32.11 ± 8.6 baseline to 19.11 ± 5.4 EOS) compared to the placebo group (from 25.23 ± 3.6 baseline to 23.2 ± 4.9 EOS), and a significant reduction (p < 0.001) of NDI-SF scoring was noted in the Asdamarin™ group (from 15.74 ± 4.1 baseline to 11.54 ± 2.1 EOS) compared to placebo group (from 12.54 ± 3.2 baseline to 11.63 ± 2.6 EOS). Asdamarin™ has been found safe and very well tolerated during the study.
功能性消化不良(FD)是一个普遍的全球健康问题,随着时间的推移而增加。受中药肝胃不和谐综合征的启发,为了寻找一种快速的天然替代治疗方法,我们开发了一种阿魏-水飞蓟(Asdamarin™)联合提取物,并通过为期7天的随机、双盲、安慰剂对照先导研究(CTRI/2018/05/013993,日期为2018年5月21日)对70名健康人类志愿者(18-60岁)进行了研究,他们每天补充250毫克/两次安慰剂或阿斯达马林™。通过胃肠道症状评定量表(GSRS)的变化、格拉斯哥消化不良严重程度评分(GDSS)的变化和Nepean生活质量消化不良指数(NDI-SF)的变化,对受试者进行从基线到研究结束(EOS)的评估。基线相比显著降低(p < 0.001)的gds问卷得分是指出Asdamarin™集团(在基线从5.66±3.1,5.09±2.8 (EOS))的研究相比安慰剂组(从2.77±1.3基线2.69±1.3 EOS),明显降低(p < 0.001)的gsr分数指出Asdamarin™集团(从32.11±8.6基线19.11±5.4 EOS)相比安慰剂组(从25.23±3.6基线23.2±4.9 EOS),与安慰剂组(从12.54±3.2基线到11.63±2.6 EOS)相比,Asdamarin™组(从15.74±4.1基线到11.54±2.1 EOS)的NDI-SF评分显著降低(p < 0.001)。在研究中发现Asdamarin™安全且耐受性良好。
{"title":"AsdamarinTM relieves functional dyspepsia in healthy adults in only 7 days: A randomized, double-blind, placebo-controlled pilot study","authors":"Daguet David, Venkataramana Sudeep Heggar, Thomas Justin V, K. Shyam Prasad","doi":"10.29328/journal.acgh.1001028","DOIUrl":"https://doi.org/10.29328/journal.acgh.1001028","url":null,"abstract":"Functional dyspepsia (FD) is a prevalent global health concern increasing with years. Inspired by the Traditional Chinese Medicine (TCM) liver-stomach disharmony syndrome in order to find a quick natural alternative treatment, a Ferula asafoetida-Silybum marianum (Asdamarin™) combined extract has been developed and proved its rapid efficiency and its safety with a 7-day randomized, double-blind, placebo-controlled pilot study (CTRI/2018/05/013993 dated 21/05/2018) conducted on 70 healthy human volunteers (aged 18–60 years) supplemented with 250 mg / twice a day of either a placebo or Asdamarin™. Subjects were evaluated from baseline to the end of the study (EOS) through changes in Gastrointestinal Symptom Rating Scale (GSRS), changes in Glasgow Dyspepsia Severity Score (GDSS) and changes in the short form of Nepean Dyspepsia Index (NDI-SF) for Quality of Life. Compared to the baseline a significant reduction (p < 0.001) of GDSS questionnaire score was noted in the Asdamarin™ group (from 5.66 ± 3.1 at baseline to 5.09 ± 2.8 at the End Of Study (EOS)) compared to placebo group (from 2.77 ± 1.3 baseline to 2.69 ± 1.3 EOS), a significant decrease (p < 0.001) of GSRS score noted in the Asdamarin™ group (from 32.11 ± 8.6 baseline to 19.11 ± 5.4 EOS) compared to the placebo group (from 25.23 ± 3.6 baseline to 23.2 ± 4.9 EOS), and a significant reduction (p < 0.001) of NDI-SF scoring was noted in the Asdamarin™ group (from 15.74 ± 4.1 baseline to 11.54 ± 2.1 EOS) compared to placebo group (from 12.54 ± 3.2 baseline to 11.63 ± 2.6 EOS). Asdamarin™ has been found safe and very well tolerated during the study.","PeriodicalId":252959,"journal":{"name":"Annals of Clinical Gastroenterology and Hepatology","volume":"135 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124558908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcome of liver transplantation for autoimmune hepatitis in South Africa 南非自身免疫性肝炎肝移植的结果
Pub Date : 1900-01-01 DOI: 10.29328/journal.acgh.1001038
Siddiqui Nida Mishraz, H. Kapila, Bobat Bilal, Parbhoo Dinen, Lala Vikash, Mahomed Adam
Background: Liver Transplantation (LT) is the definitive treatment for Autoimmune Hepatitis (AIH) in patients with decompensated cirrhosis, liver failure and hepatocellular carcinoma. Outcomes of LT in AIH among black-Africans are not well-defined. We performed a single-center retrospective-review of adult LT patients. The study period was from 1st August 2004-31st August 2019. The primary aim was to document 1- & 5- year patient and graft survival. A secondary aim was to compare the survival of black-Africans to Caucasians. Data was analyzed using survival-analysis. Results: A total of 56 LT were performed for AIH. Sixty-seven percent (n = 38/56) had confirmed AIH on explant histology. Of these, the majority i.e., 79% (30/38) were female and 21% (8/38) were male. There were equal numbers of black-African 42% (n = 16/38) and Caucasian 42% (n = 16/38) patients. Rejection was four-times higher in black-Africans as compared to Caucasians. Forty-four percent (n = 17/38) had an acute rejection episode and 13% (5/38) had chronic rejection. Recurrence was found in four black-African females. Post-LT patient survival at 1- and 5- years was 86.5% and 80.7%, and graft survival was 94% and 70.8% respectively. The 5- year patient survival was insignificantly lower for black-Africans (73.9%) as compared to Caucasians (83.7%) (p - value 0.26, CI 6.3 - 12.2). Five-year graft survival was significantly lower among black-Africans (55%) as compared to Caucasians (84.8%) (p - value 0.003 CI 3.8 - 8.1) Conclusion: Black-Africans had a four-fold higher rate of rejection compared to Caucasians. Recurrent AIH was only found in patients of black ethnicity. Similar 1- & 5- year patient survival rates were observed between the two ethnicities. The 5-year graft survival among black-Africans was significantly lower than Caucasians.
背景:肝移植(LT)是自身免疫性肝炎(AIH)失代偿性肝硬化、肝功能衰竭和肝细胞癌患者的最终治疗方法。非洲黑人AIH患者LT治疗的结果尚不明确。我们对成人肝移植患者进行了单中心回顾性研究。研究期间为2004年8月1日至2019年8月31日。主要目的是记录1年和5年患者和移植物的生存。第二个目的是比较非洲黑人和高加索人的生存状况。采用生存分析对数据进行分析。结果:AIH共行肝移植56例。67% (n = 38/56)的外植体组织学证实AIH。其中,大多数,即79%(30/38)为女性,21%(8/38)为男性。黑非洲患者占42% (n = 16/38),高加索患者占42% (n = 16/38)。非洲黑人的拒绝率是白种人的四倍。44% (n = 17/38)发生急性排斥反应,13%(5/38)发生慢性排斥反应。在4名非洲黑人女性中发现复发。移植后患者1年和5年生存率分别为86.5%和80.7%,移植物生存率分别为94%和70.8%。非洲黑人患者的5年生存率(73.9%)低于高加索人(83.7%)(p值0.26,CI 6.3 - 12.2)。非洲黑人的5年移植存活率(55%)明显低于白种人(84.8%)(p值0.003 CI 3.8 - 8.1)结论:非洲黑人的排异率是白种人的4倍。复发性AIH仅见于黑人患者。在两个种族之间观察到相似的1年和5年患者生存率。非洲黑人的5年移植物存活率明显低于白种人。
{"title":"Outcome of liver transplantation for autoimmune hepatitis in South Africa","authors":"Siddiqui Nida Mishraz, H. Kapila, Bobat Bilal, Parbhoo Dinen, Lala Vikash, Mahomed Adam","doi":"10.29328/journal.acgh.1001038","DOIUrl":"https://doi.org/10.29328/journal.acgh.1001038","url":null,"abstract":"Background: Liver Transplantation (LT) is the definitive treatment for Autoimmune Hepatitis (AIH) in patients with decompensated cirrhosis, liver failure and hepatocellular carcinoma. Outcomes of LT in AIH among black-Africans are not well-defined. We performed a single-center retrospective-review of adult LT patients. The study period was from 1st August 2004-31st August 2019. The primary aim was to document 1- & 5- year patient and graft survival. A secondary aim was to compare the survival of black-Africans to Caucasians. Data was analyzed using survival-analysis. Results: A total of 56 LT were performed for AIH. Sixty-seven percent (n = 38/56) had confirmed AIH on explant histology. Of these, the majority i.e., 79% (30/38) were female and 21% (8/38) were male. There were equal numbers of black-African 42% (n = 16/38) and Caucasian 42% (n = 16/38) patients. Rejection was four-times higher in black-Africans as compared to Caucasians. Forty-four percent (n = 17/38) had an acute rejection episode and 13% (5/38) had chronic rejection. Recurrence was found in four black-African females. Post-LT patient survival at 1- and 5- years was 86.5% and 80.7%, and graft survival was 94% and 70.8% respectively. The 5- year patient survival was insignificantly lower for black-Africans (73.9%) as compared to Caucasians (83.7%) (p - value 0.26, CI 6.3 - 12.2). Five-year graft survival was significantly lower among black-Africans (55%) as compared to Caucasians (84.8%) (p - value 0.003 CI 3.8 - 8.1) Conclusion: Black-Africans had a four-fold higher rate of rejection compared to Caucasians. Recurrent AIH was only found in patients of black ethnicity. Similar 1- & 5- year patient survival rates were observed between the two ethnicities. The 5-year graft survival among black-Africans was significantly lower than Caucasians.","PeriodicalId":252959,"journal":{"name":"Annals of Clinical Gastroenterology and Hepatology","volume":"64 3 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130572613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Annals of Clinical Gastroenterology and Hepatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1